Effect of Biological Disease-modifying Anti-rheumatic Drugs on Airway and Interstitial Lung Disease in Patients with Rheumatoid Arthritis-Reference-Cited by-同舟云学术

Effect of Biological Disease-modifying Anti-rheumatic Drugs on Airway and Interstitial Lung Disease in Patients with Rheumatoid Arthritis

Published:2019-06-15 Issue:12 Volume:58 Page:1703-1712
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Kurata Izumi¹,Tsuboi Hiroto¹,Terasaki Mayu¹,Shimizu Masaru¹,Toko Hirofumi¹,Honda Fumika¹,Ohyama Ayako¹,Yagishita Mizuki¹,Osada Atsumu¹,Ebe Hiroshi¹,Kawaguchi Hoshimi¹,Takahashi Hiroyuki¹,Hagiwara Shinya¹,Asashima Hiromitsu¹,Kondo Yuya¹,Matsumoto Isao¹,Sumida Takayuki¹

Affiliation:

1. Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Japan

Publisher

Japanese Society of Internal Medicine

Subject

General Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/58/12/58_2226-18/_pdf

Reference33 articles.

1. 1. Geddes DM, Webley M, Emerson PA. Airways obstruction in rheumatoid arthritis. Ann Rheum Dis 38: 222-225, 1979.

2. 2. Hassan WU, Keaney NP, Holland CD, Kelly CA. Bronchial reactivity and airflow obstruction in rheumatoid arthritis. Ann Rheum Dis 53: 511-514, 1994.

3. 3. Fischer A, Brown KK, Du Bois RM, et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol 40: 640-646, 2013.